ArticlePhysiological reports2025
CORM-A1 delivers carbon monoxide to the kidney and alleviates post-ischemic renal dysfunction in rat and swine models.
Article in Physiological reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Carbon monoxide-releasing molecule CORM-401 treatment elicits corticosterone-driven stress lipolysis and tissue-specific hypoxia-inducible factor activation.Redox biology · 2026Article
- CORM-A1 delivers carbon monoxide to the kidney and alleviates post-ischemic renal dysfunction in rat and swine models.Physiological reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Carbon monoxide (CO), a gas endogenously produced in mammalian tissues, exerts vasodilatory, anti-ischemic, and anti-inflammatory effects. These properties have prompted the development of CO-releasing molecules (CO-RMs) for therapeutic purposes. Among this class of compounds is CORM-A1, a boron-based carboxylic acid, which generates controlled amounts of CO under physiological conditions. In this proof-of-principle study we explored the potential of CORM-A1 to protect kidneys from warm ischemia and reperfusion (WI/R) injury in rat and swine models. We found that intravenous administration of CORM-A1 significantly increased blood carboxyhemoglobin (COHb) levels while facilitating CO accumulation in renal tissue, thus confirming its ability to deliver CO to peripheral organs. In rats subjected to 45- and 60-min WI/R, administration of CORM-A1 improved renal function at reperfusion, as shown by decreased serum creatinine and urea levels. Histopathological analysis revealed substantial protection against tubular damage, cell infiltration, and inflammation, especially after 60-min ischemia. Protection was dose-dependent, with higher doses offering enhanced effects. In a swine kidney auto-transplantation model, CORM-A1 significantly improved graft function, reduced fibrosis and necrosis, and extended graft survival. These findings position CORM-A1 as a promising CO prodrug, with translational relevance for clinical applications in kidney transplantation and other ischemia-related conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.